Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS.

Clinical staging of chronic lymphocytic leukemia.
Blood 1975; 46: 219-234.
Description: Proposed Clnical staging as a predictor of survival.

Binet JL, Auquier A, Dighiero G, et al.

A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis.
Cancer 1981; 48: 198-206
Description: Cox multivariate analysis of survival identifying prognostic factors at diagnosis

Cheson BD, Bennett JM, Grever M, et al.

Natinal Cancer Institute –sponsored Working Group guidenlines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatement.
Blood 1996; 87: 4990-4991.

Dighiero G, Maloum K, Desablens B, Cazin B, Navaroo M, Leblay R, Leporrier M, Jaubert J, Lepeu G, Dreyfus B, Binet JL, Travade P.

Chlorambucil in indolent chronic lymphocytic leukemia. French Cooperative Group on Chronic Lymphocytic Leukemia.
N Engl J Med. 1998 May 21; 338(21): 1506-14.
Description: Two randomized clinical trials testing deferment of therapy until disease progression.

Raphael B, Andersen JW, Silber R, Oken M, Moore D, Bennett J, Bonner H, Hahn R, Knospe WH, Mazza J, et al.

Comparison of chlorambucil and prednisone versus cyclophosphamide, vincristine, and prednisone as initial treatment for chronic lymphocytic leukemia: long-term follow-up of an Eastern Cooperative Oncology Group randomized clinical trial.
J Clin Oncol. 1991 May; 9(5):770-6.
Description: Randomized clinical testing intermittent alkylator therapy and a more intensive regimen in patients with advanced disease.

CLL Trialists’ Collaborative Group

Chemotherapeutic options in chronic lymphocytic leukemia: a meta-analysis of the randomized trials.
J Natl Cancer Inst 1999;91:861-868.
Description: Meta-analysis comparing the effects of survival on immediate versus deferred therapy and comvination versus single-agent therapy as first-line treatment for advanced disease.

Johnson S, Smith AG, Loffler H, Osby E, Juliusson G, Emmerich B, Wyld PJ, Hiddemann W.

Multicentre prospective randomized trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia.
The French Cooperative Group on CLL.
Lancet. 1996 may 25; 347(9013):1432-8

Rai KR, Peterson BL, Appelbaum FR, Kolitz J, Elias L, Shepherd L, Hines J, Threatte GA, Larson RA, Cheson BD, Schiffer CA.

Fludarabine compared with chlrambucil as primary therapy for chronic lymphocytic leukemia.
N Engl J Med 2000 Dec 14;343(24): 1432-8

Rai KR, Peterson BL, Appelbaum FR, Kolitz J, Elias L, Shepherd L, Hines J, Threatte GA, Larson RA, Cheson BD, Schiffer CA.

Bludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia.
N Engl J Med. 2000 Dec 14; 343(24):1750-7.

Leporrier M, Chevret S, Cazin B, Boudjerra N, Feugier P, Desablens B, Rapp MJ, Jaubert J, Autrand C, Divine M, Dreyfus B, Maloum K, Travade P, Dighiero G, Binet JL, Chastang C

French Cooperative Group on Chronic Lymphocytic Leukemia.
Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients.
Blood 2001 Oct 15;98(8):2319-25

Robak T, Blonki JZ, Kasznicki M, Blasinska-Morawiec M, Krykowski E, Dmoszynska A, Mrugala-Spiewak H, Skotnicki AB, Nowak W, Konopka L, Ceglarek B, Maj S, Dwilewicz-Trojaczek J, Hellmann A, Urasinski I, Zdziarska B, Kotlarek-Haus S, Potoczek S, Grieb P.

Cladribine with prednisone versus chlorambucil with prednisone as first-line therapy in chronic lymphocytic leukemia: report of a prospective, randomized, multicenter trial.
Blood 2000 Oct 15;96(8): 2723-9.

Keating MJ, Flinn I, Jain V, Binet JL, Hillmen P, Byrd J, Albitar M, Brettman L, Santabarbara P, Wacker B, Rai KR.

Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study.
Blood 2002 May 15; 99(10):3554-61

O’Brien SM, Kantarijian H, Thomas DA, Giles FJ, Freireich EJ, Cortes J, Lerner S, Keatinig MJ.

Rituximab dose-escalation trial in chronic lymphocytic leukemia.
J Clin Oncol 2001 Apr 15;19(8):2165-70

Huhn D, von Schilling C, Wilhelm M, Ho AD, Hallek M, Kuse R, Knauf W, Riedel U, Hinke A, Srock S, Serke S, Peschel C, Emmerich B; German Chronic Lymphocytic Leukemia Study Group.

Rituximab therapy of patients with B-cell chronic lymphocytic leukemia.
Blood 2001 Sep 1;98(5):1326-31

Anaissie EJ, Kontoyiannis DP, O’Brien S, Kantarjian H, Robertson L, Lerner S, Keating MJ.

Infections in patients with chronic lymphocytic leukemia treated with fludarabine.
Ann Intern Med. 1998 Oct 1;129(7):559-66

Mauro FR, Foa R, Cerretti R, Giannarelli D, Coluzzi S, Mandelli F, Girelli G.

Autoimmune hemolytic anemia in chronic lymphocytic leukemia: clinical, therapeutic, and prognostic features.
Blood 2000 May 1;95(9):2786-92

Cooperative Group for the Study of Immunoglobulin in Chronic Lymphocytic Leukemia.
Intravenous immunoglobulin for the prevention of infection in chronic lymphocytic leukemia.

A randomized, controlled clinical trial
N Engl J Med.
1988 Oct 6;319(14):902-7

van Besien K, Keralavarma B, Devine S, Stock W.

Allogeneic and autologous transplantation for chronic lymphocytic leukemia.
Leukemia 2001 Sep;15(9):1317-25

Dohner H, Stilgenbauer S, Benner A, Leupolt E, Krober A, Bullinger L, Dohner K, Bentz M, Lichter P.

Genomic aberrations and survival in chronic lymphocytic leukemia.
N Engl J Med 2000 Dec 28;343(26):1910-6.
A correlative study defining prognostic subsets of CLL patients based upon karyotypic abnormalities.

Return to Table of Contents